---
schema_version: "secwatch.filing_event.v1"
accession: "0000832101-23-000038"
form_type: "8-K"
ticker: "IEX"
cik: "0000832101"
company_name: "IDEX CORP /DE/"
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T02:09:58.595492+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# IDEX eliminates position of SVP Group Executive Health & Science Technologies

## Summary
- Marc Uleman's role eliminated effective September 11, 2023, due to internal reorganization.
- Mr. Uleman will no longer serve in an executive role at IDEX.
- No successor has been named for the eliminated position.

## SEC filing metadata
- accession: 0000832101-23-000038
- form_type: 8-K
- ticker: IEX
- cik: 0000832101
- company_name: IDEX CORP /DE/
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832101/000083210123000038/0000832101-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832101/000083210123000038/iex-20230824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000832101-23-000038
- JSON: https://secwatch.observer/filing/0000832101-23-000038.json
- Plain text: https://secwatch.observer/filing/0000832101-23-000038.txt

## Key facts
- Executive change
  Marc Uleman departed as Senior Vice President, Group Executive, Health & Science Technologies at IDEX CORP /DE/.
  - Action: eliminated
  - Role: Senior Vice President, Group Executive, Health & Science Technologies
  source text: IDEX Corporation notified Marc Uleman, Senior Vice President, Group Executive, Health & Science Technologies, of the elimination of his position, effective September 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832101/000083210123000038/0000832101-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.